Scholarlink

<p>It was aimed to investigate the frequency of metabolic dysfunction–associated steatotic liver disease (MASLD) in type 2 diabetes mellitus (T2DM) patients with non-invasive tests. We prospectively evaluated the frequency of MASLD and fibrosis stage of the liver with biomarkers based on blood tests and FibroScan<sup>®</sup> in adult patients with T2DM who were followed up from the outpatient clinic in a tertiary center. Liver stiffness measurement (LSM) ≥ 8&#xa0;kPa was accepted as clinically significant fibrosis (≥ F2), and ≥ 12&#xa0;kPa was accepted as advanced fibrosis (F3-4) in FibroScan<sup>®</sup> measurements. The cut-off value of the CAP score was accepted as 275 dB/m for steatosis. There were 504 patients with T2DM in the study. 54.2% were female. 252 (50%) patients had MASLD. 30.6% had clinically significant fibrosis, and 13.5% had advanced fibrosis. The degree of steatosis in the patients increased, the frequency of clinically significant fibrosis increased (<i>p</i> &lt; 0.05). The frequency of MASLD significantly increased as BMI increased (<i>p</i> &lt; 0.05). Diabetic nephropathy and neuropathy were more common in MASLD patients (<i>p</i> &lt; 0.05). There was a significant relationship between clinically significant fibrosis and nephropathy (<i>p</i> &lt; 0.001). MASLD and significant liver fibrosis are highly common in patients with T2DM. As the severity of liver steatosis increases, fibrosis stage progresses.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A prospective study on the role of non-invasive tests in the evaluation of diabetes mellitus associated steatotic liver disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月8日

查看全文
  • Zülal İstemihan,
  • Fatih Bektaş,
  • Ali Emre Bardak,
  • Cansu Kızıltaş,
  • Gamze Kemeç,
  • Ziya İmanov,
  • İbrahim Volkan Şenkal,
  • Kanan Nuriyev,
  • Aynura Rustamzade,
  • Sezen Genç Uluçeçen,
  • Hülya Hacisahinogullari,
  • Kubilay Karşıdağ,
  • Bilger Çavuş,
  • Aslı Çifcibaşı Örmeci,
  • Filiz Akyüz,
  • Kadir Demir,
  • Fatih Beşışık,
  • Sabahattin Kaymakoğlu

摘要

It was aimed to investigate the frequency of metabolic dysfunction–associated steatotic liver disease (MASLD) in type 2 diabetes mellitus (T2DM) patients with non-invasive tests. We prospectively evaluated the frequency of MASLD and fibrosis stage of the liver with biomarkers based on blood tests and FibroScan® in adult patients with T2DM who were followed up from the outpatient clinic in a tertiary center. Liver stiffness measurement (LSM) ≥ 8 kPa was accepted as clinically significant fibrosis (≥ F2), and ≥ 12 kPa was accepted as advanced fibrosis (F3-4) in FibroScan® measurements. The cut-off value of the CAP score was accepted as 275 dB/m for steatosis. There were 504 patients with T2DM in the study. 54.2% were female. 252 (50%) patients had MASLD. 30.6% had clinically significant fibrosis, and 13.5% had advanced fibrosis. The degree of steatosis in the patients increased, the frequency of clinically significant fibrosis increased (p < 0.05). The frequency of MASLD significantly increased as BMI increased (p < 0.05). Diabetic nephropathy and neuropathy were more common in MASLD patients (p < 0.05). There was a significant relationship between clinically significant fibrosis and nephropathy (p < 0.001). MASLD and significant liver fibrosis are highly common in patients with T2DM. As the severity of liver steatosis increases, fibrosis stage progresses.